Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy

Journal of Evaluation in Clinical Practice

Volumn 23, Issue 3, 2017, Pages 486-493

  Wabe, Nasir ^a   Wiese, Michael D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

medication adherence; physician adherence; treat to target; treatment outcome

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ARTICLE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH CARE NEED; HUMAN; LONG TERM CARE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT REFERRAL; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT OUTCOME; TREATMENT REFUSAL; CLINICAL PRACTICE; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ARTHRITIS, RHEUMATOID; GUIDELINE ADHERENCE; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84997707912     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/jep.12620     Document Type: Article

References (49)

1. Lee DM, Weinblatt ME. (2001) Rheumatoid arthritis. Lancet, 358 (9285), 903–911.
2. Boonen A, Severens J. The burden of illness of rheumatoid arthritis. Clinical Rheumatology, 30 (1), 3–8.
3. Lutze U, Archenholtz B. (2007 Mar) The impact of arthritis on daily life with the patient perspective in focus. Scandinavian Journal of Caring Sciences, 21 (1), 64–70.
4. Shanahan EM, Smith M, Roberts-Thomson L, Esterman A, Ahern M. (2008) Influence of rheumatoid arthritis on work participation in Australia. Internal Medicine Journal, 38(3), 166–173.
5. Verstappen SM, Bijlsma JW, Verkleij H, et al. (2004) Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Care and Research, 51(3), 488–497.
6. O'Dell JR, Haire CE, Erikson N, et al. (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. The New England Journal of Medicine, 334 (20), 1287–1291.
7. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet, 353 (9164), 1568–1573.
8. Kukar M, Petryna O, Efthimiou P. (2009) Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics, 3, 443–457.
9. Scott DL, Wolfe F, Huizinga TWJ. (2010) Rheumatoid arthritis. The Lancet, 376 (9746), 1094–1108.
10. Pincus T, Castrejon I. (2013) Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis (2013), 71 (Suppl 1), S33–S40.
11. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430), 263–269.
12. Verstappen SM, Jacobs JW, van der Veen MJ, et al. (2007 Nov) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the Rheumatic Diseases, 66 (11), 1443–1449. Epub 2007 May 22
13. Quinn MA, Emery P. (2003 Sep-Oct) Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clinical and Experimental Rheumatology, 21 (5 Suppl 31), S154–S157.
14. Smolen JS, Aletaha D, Bijlsma JW, et al. (2010 Apr) Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 69 (4), 631–637. doi: 10.1136/ard.2009.123919 Epub 2010 Mar 9
15. Smolen JS, Breedveld FC, Burmester GR, et al. (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 75 (1), 3–15.
16. Vrijens B, De Geest S, Hughes DA, et al. (2012) A new taxonomy for describing and defining adherence to medications. British Journal of Clinical Pharmacology, 73 (5), 691–705.
17. Pasma, A. (2015). Non-adherence to disease-modifying antirheumatic drugs in early arthritis.
18. Wabe N, Sorich M, Wechalekar M, et al. (2015) Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Research & Therapy, 17 (1), 48
19. Aronson JK. (2007) Time to abandon the term ‘patient concordance’. British Journal of Clinical Pharmacology, 64 (5), 711–713.
20. Cramer JA, Roy A, Burrell A, et al. (2008) Medication compliance and persistence: terminology and definitions. Value in Health, 11 (1), 44–47.
21. Sabaté, E. (2003). Adherence to long-term therapies: evidence for action: World Health Organization.
22. Salt E, Frazier SK. (2010) Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthopaedic Nursing, 29 (4), 260–275.
23. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W. (1999) Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. The Journal of Rheumatology, 26 (10), 2114–2122.
24. Blum MA, Koo D, Doshi JA. (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clinical Therapeutics, 33 (7), 901–913.
25. Choudhry NK, Fischer MA, Avorn J, et al. (2011) The implications of therapeutic complexity on adherence to cardiovascular medications. Archives of Internal Medicine, 171 (9), 814–822.
26. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Review of Clinical Immunology. 2012;8(4), 337–351.
27. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. (2003) Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value in Health, 6 (5), 566–573.
28. De Klerk E, Van der Heijde D, Van der Tempel H, Van Der Linden S. (1999) Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. The Journal of Rheumatology, 26 (12), 2635–2641.
29. Pasma A, van't Spijker A, Hazes JM, Busschbach JJ, Luime JJ. (2013) Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Seminars in Arthritis and Rheumatism, 43 (1), 18–28.
30. van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. (2009 Oct) Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. The Journal of Rheumatology, 36 (10), 2164–2170. doi: 10.3899/jrheum.081204 Epub 2009 Sep 1
31. Horwitz RI, Viscoli CM, Berkman L, et al. (1990) Treatment adherence and risk of death after a myocardial infarction. Lancet, 336(8714), 542–545.
32. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. (1990) The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA, 263 (12), 1653–1657.
33. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. (2010) Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. The American Journal of the Medical Sciences, 340 (4), 282–290.
34. Cannon GW, Mikuls TR, Hayden CL, et al. (2011) Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken), 63 (12), 1680–1690.
35. Contreras-Yanez I, Cabiedes J, Villa AR, Rull-Gabayet M, Pascual-Ramos V. (2010 Sep-Oct) Persistence on therapy is a major determinant of patient-, physician- and laboratory- reported outcomes in recent-onset rheumatoid arthritis patients. Clinical and Experimental Rheumatology, 28 (5), 748–751. Epub 2010 Oct 22
36. Pascual-Ramos V, Contreras-Yanez I, Villa AR, Cabiedes J, Rull-Gabayet M. (2009) Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Research & Therapy, 11 (1), R26. doi: 10.1186/ar2620 Epub 2009 Feb 19
37. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. (1999) Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ, 318 (7182), 527–530.
38. Vermeer M, Kuper HH, Bernelot Moens HJ, et al. (2012) Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Research & Therapy, 14 (6), R254
39. Kuusalo L, Puolakka K, Kautiainen H, et al. (2015) Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. Scandinavian Journal of Rheumatology, 1–7.
40. Markusse IM, Dirven L, Han KH, et al. (2015) Evaluating adherence to a treat-to-target protocol in recent-onset rheumatoid arthritis: reasons for compliance and hesitation. Arthritis Care Res (Hoboken).
41. Waimann, C. A., Citera, G., Dal Pra, F., Celeste Orozco, M., Ceccatto, F., Paira, S., Gauna, M., Secco, A., Mamani, M., & Marino, L. (2014). Adherence to a treat-to-target (T2T) strategy in early rheumatoid arthritis. Is it feasible in daily clinical practice?. Paper presented at the ARTHRITIS & RHEUMATOLOGY.
42. Buch M, O'Reilly D, Sheeran T, Keidel S, Emery P. (2015) Compliance with treat to target recommendations on rheumatoid arthritis and patient outcomes: interim results of a UK Multicentre Study. Rheumatology, 54 (suppl 1), i97
43. Haraoui B, Smolen JS, Aletaha D, et al. (2011) Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Annals of the Rheumatic Diseases, 70 (11), 1999–2002.
44. Haraoui B, Bensen W, Bessette L, Le Clercq S, Thorne C, Wade J. (2012) Treating rheumatoid arthritis to target: a Canadian physician survey. The Journal of Rheumatology, 39 (5), 949–953.
45. Kaneko Y, Koike T, Oda H, et al. (2015) Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. Modern Rheumatology, 25 (1), 43–49.
46. Lindsay K, Ibrahim G, Sokoll K, Tripathi M, Melsom RD, Helliwell PS. (2009) The composite DAS score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. Journal of Clinical Rheumatology, 15 (5), 223–225.
47. Taylor WJ, Harrison AA, Highton J, et al. (2008) Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology (Oxford), 47 (4), 514–518.
48. Wabe NT, Sorich NT, Wechalekar MD et al. (2016) Effect of adherence to protocolized targeted intensifications of disease modifying antirheumatic drugs ontreatment outcomes in rheumatoid arthritis: Results from an australian early arthritis cohort. Journal of Rheumatol, 43 (9), 1643–1649.
49. Bergman, M. J., Shaw, J. W., Cifaldi, M. A., Guerin, A., Chopra, P., & Signorovitch, J. (2012). Benefits of treat-to-target guideline compliance in patients with rheumatoid arthritis: a retrospective claims analysis. Paper presented at the ARTHRITIS AND RHEUMATISM.